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ABSTRAK
Kanker kolorektal (KKR) merupakan kanker urutan ketiga terbanyak pada laki-laki dan kedua pada 
perempuan, dan penyebab kematian ke dua akibat kanker di dunia. Indonesia dengan penduduk sekitar 250 
juta dan incidence rate KKR per 100.000 populasi 15,2 untuk laki-laki dan 10,2 perempuan, diperkirakan 
memiliki 63.500 kasus per tahun. Lebih dari 50% penderita KKR akan mengalami metastasis. KKR masih 
merupakan penyebab utama kematian akibat kanker, dan dari sejumlah pasien yang telah menjalani operasi 
KKR, sebagian akan kambuh kembali. Kemoterapi juga mempunyai beberapa tantangan termasuk adanya 
resistensi terhadap kemoterapi. Pemeriksaan molekuler jaringan tumor menjadi penting dan mempunyai 
implikasi dalam pemilihan terapi. Pemeriksaan biomarker dapat digunakan untuk penilaian prognosis, faktor 
prediksi dan target terapi. Penelitian terkini menunjukkan bahwa cancer stem cells (CSCs) merupakan sumber 
tumorigenesis, perkembangan, metastasis dan penyebab kambuhnya kanker. Tinjauan ini mengemukakan masalah 
terkait CSCs dan perkembangan obat masa depan yang ditujukan untuk CSCs. 
Kata kunci: kanker kolorektal, cancer stem cells, biomarker, kemoresisten, target terapi.
ABSTRACT
Colorectal cancer (CRC) is the third most frequent cancer in males, the second in females, and is the second 
leading cause of cancer related death worldwide. Within Indonesia’s 250 million population, the incidence rates 
for CRC per 100,000 population were 15.2 for males and 10.2 for females, and estimated 63,500 cases per year. 
More than 50% of colorectal cancer patients will develop metastasis. CRC is still the main cause of tumor-
related death, and although most CRC patients are treated with surgery to remove the tumor tissue, some of the 
CRC patients recurred. Chemotherapy used as adjuvant or neoadjuvant therapy also has several problems, in 
which these treatments are useless in tumor cells with chemo-resistance. Molecular testing of CRC from tumor 
tissues has important implications for the selection of treatment. Biomarkers can be used as prognostic value, 
molecular predictive factors, and targeted therapy. Recent research reported that, cancer stem cells (CSCs) 
are considered as the origin of tumorigenesis, development, metastasis and recurrence. At present, it has been 
shown that CSCs existed in many tumors including CRC. This review aims to summarize the issue on CSCs, 
and the future development of drugs that target colorectal cancer stem cells.
Keywords: colorectal cancer, cancer stem cells, biomarkers, chemoresistance, target therapy.
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INTRODUCTION
Colorectal cancer (CRC) is the third most 
most frequent cancer in males, the second in 
females, and the second leading cause of cancer 
death worldwide, with estimated 1.4 milion new 
cases and 693,900 deaths in 2012. Indonesia, 
with its 250 million population, has age-
standardized incidence rates for colorectal cancer 
per 100,000 population were 15.2 for males and 
10.2 for females, and has estimated 63,500 cases 
per year, and an almost similar burden to other 
countries with increasing populations.1-3
Despite advanced treatment strategies, 
the disease is rarely cured completely due to 
recurrence. Evidence shows that this is due to 
a small population of cells, called cancer stem 
cells (CSCs), in the tumor mass that have the 
self-renewal and differentiation potential to give 
rise to a new tumor population. Tumor recurrence 
remains a major challenge in the treatment of 
CRC, due to the presence of the CSC population 
which contributes to chemo-resistance.4
Sporadic CRC derives from somatic 
mutations, and is not associated with family 
history. CRC is a heterogeneous complex of 
diseases. Progression to  CRC is considered 
a multi-step process, with an accumulation 
of various genetic and epigenetic alterations, 
leading to transformation from a normal cell to 
a premalignant tumor and finally to malignant 
and potentially metastatic tumor.5-8
Clinical applications of the molecular 
biological marker status of CRC patiens are 
the important factors to determine either the 
possibility of successful treatment or response 
of chemotherapy (i.e. predictive factor) or life 
expectancy (i.e. prognostic factor). Cancer 
locations, whether the tumor is at proximal, distal 
colon or rectum, are also different in their associated 
molecular alterations in carcinogenesis, and also 
in the treatment response with chemotherapy.9-12 
Approved target therapy for CRC consists of the 
anti epidermal growth factor receptor (anti-EGFR) 
cetuximab, and anti vascular endothelial growth 
factor receptor (anti-VEGF monoclonal antibody) 
bevacizumab. KRAS mutations predict lack of 
response to therapy with anti-EGFR. CRC with 
MSI-high status is said to be resistant to 5-FU.13-16
Recent research reported that cancer stem 
cells (CSCs) are considered as the origin of tumor 
genesis, development, metastasis and recurence 
in theory. At present, it has been proved that, 
CSCs exist in many tumors including CRC.17-18
MOLECULAR BIOLOGY TESTS
Treatment approache by using the molecular 
test results of CRC tumor tissue will give 
information for the selection of individualized 
therapy, representing the principles of 
personalized tumor diagnostics and targeted 
therapy. Fresh tissue is obtained from colorectal 
tumors, either by colonoscopic biopsy or surgery. 
Tumor tissues are immediately fixated by using 
10% formaldehyde buffering solution and 
made into paraffin blocks or formalin-fixed and 
paraffin-embedded tissues (FFPET. It is used 
for the examination of histology of the tumor, 
and immunohistochemical test (IHC) for the 
evaluation of the protein expression negative 
(PEN) of chromosomal instability (CIN), and 
DNA-mismatch repair protein (MMR) defect or 
the assessment of microsatellite instability (MSI) 
status. Tumor tissue is also used for examining 
MSI by polymerase chain reaction (PCR), and 
CpG island methylation phenotype (CIMP) 
status.11,19,20,21
Chromosomal Instability (CIN)
It is suggested that CIN is the most common 
(80-85%) genomic instability of all CRC and 
adenomas. CIN induces carcinoma through the 
loss or mutation of tumor suppressor genes, such 
as APC, TP53, and also through activation of 
oncogens such as KRAS. CRC caused by CIN 
usually have poor prognosis. KRAS gene plays 
the most important role. The activation of RAS 
genes can promote cell survival and suppress 
apoptosis. Most KRAS mutations occur in codon 
12 (70-80%), and codon 13 of exon 2. KRAS 
mutation analysis is widely used as a prognostic 
and predictive biomarker in treating CRC 
patients, to predict the therapeutic effectiveness 
of anti-EGFR monoclonal antibody (such as 
cetuximab and panitumumab). KRAS mutations 
predict lack of response to those anti-EGFR. 
Mutations in BRAF occur in approximately 
12% of all CRCs patients and it is mutually 
exclusive of KRAS mutation. Investigation 
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of BRAF mutations is also recomended when 
KRAS mutation are not found. Adenomaous 
polyposis coli (APC) gene plays a crucial role in 
the Wnt/Wingless pathway. APC gene is the most 
important gatekeeper of colonic epithelial cell 
proliferation and it is responsible for controlling 
the underlying oncoprotein called β-catenin. 
The loss of function in APC gene may lead to 
the transition to adenoma from normal colonic 
mucosa due to the up-regulation of  β-catenin. 
Somatic APC mutations are present in most 
sporadic colorectal adenomas and cancers. 
Similar to KRAS, APC mutations appear in the 
early stage of the progression from adenoma to 
carcinoma.6,20,21
Deoxyribonucleic Acid (DNA) Mismatch 
Repair (DNA-MMR) and Microsatellite 
Instability (MSI)
Approximately 15% of all CRCs show 
underlying defects in DNA-MMR (dMMR) and 
the tumor tissues show MSI positive or MSI 
high (MSI-H). Furthermore, 3-5% MSI-H of 
CRC patients harbor germline mutations related 
to the Lynch syndrome and 12% are sporadic 
colorectal cancer.22 MSI-H status is correlated 
with the tumors being in the proximal colon and 
improved survival. At least six different genes 
(e.g. MSH2, MLH1, PMS1, hPMS2, MSH6, and 
MLH3) encode the MMR system. CRC patients 
with MSI-H status receiving fluorouracil (5-FU) 
showed no improvement in disease-free survival, 
and infact it was associated with reduced overall 
survival.11,19,21
The underlying cause of MSI-H can be 
explained by two mechanism: 1) defective MMR 
system, in which both allels of a MMR gene 
(e.g. MLH1, MSH2, MSH6, and PMS2) are 
non-functional. This results in the loss of ability 
to repair DNA replication mismatches in the 
affected cells; 2) hypermethylation of promoter 
in MMR genes that suppress the expression of 
the genes like MLH1.6,20,23
In our sudy, there were the differences in 
the characteristics of CIN, MMR, and MSI-H 
found in colorectal cancer patients based on 
different locations. The protein expression 
negative were examined by IHC for APC, MMR 
(MLH1, MSH2, MSH6 and PMS2), and for 
MSI-H by PCR based on 5 markers of BAT25, 
BAT26, D2S123, D5S346, D17S250. MSI-H 
was considered if there were ≥ 2 of abnormal 
markers.11,12
The MSI classification system is highly 
valuable in prognosis and therapy since 
chemotherapy using 5-fluorouracil is not 
efffective in treating MSI-H tumors. Instead 
irinotecan-containing regimens have shown 
improved responses and better prognosis for 
MSI-H tumors.23,24
Epigenetic Gene Silencing
Cancers with high degree of DNA-
methylation can be considered as CpG island 
methylation phenotype (CIMP) positive, and 
it encompasses 35-40% of sporadic CRC. CpG 
hypermethylation can lead to silencing of tumor-
suppressor genes in carcinogenesis since the 
expression of the genes is repressed. In some 
cases, the presence of epigenetic silencing 
overlapps with MSI-H. Some sporadic CRC 
with MSI-H is caused by DNA methylation.6,20,25
MicroRNAs (miRNAs)
MicroRNAs are small non-coding RNA that 
are usually 19-23 nucleotids in length. Due to 
their small size, miRNAs are more stable in blood 
and FFPE tissues than other nucleic acids such as 
DNA and RNA. miRNAs are involved in post-
transcriptional regulation of gene expression. 
Therefore, they are able to function as oncogens 
or tumor suppressor genes, and dysregulation of 
miRNAs would be associated with cancers. The 
miR-135a and miR-135b play important roles 
in the regulation of the Wnt/Wingless pathway 
by down-regulating APC gene expression. 
miR-17-3p and miR-92a have been found to be 
elevated in plasma and their levels decreased 
after removal of the cancer tissues. These results 
suggested that circulating miR-92 and miR-17 
are potential non-invasive diagnostic markers for 
CRC. Apart from the miRNAs mentioned above, 
miR-211 is also believed to be a potential marker 
for the diagnosis and prognosis of CRC.21,26,27
Cancer Stem Cells (CSCs)
Most cancers are heterogeneous and show 
functional and phenotypical differences at the 
cell population level. Evidence continues to 
accumulate showing that tumors containing 
a minority population of cells responsible for 
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tumor initiation, growth, and recurrence. These 
are termed “cancer stem cells” (CSCs).28 CSCs 
possess both the self-renewal and differentiation 
capabilities or tumor-initiation capabilities of 
CSCs. Moreover, recent studies have revealed 
that these CSCs is responsible for chemotherapy 
resistance within a tumor. Several mechanisms of 
chemoresistance have been proposed, including 
several signaling pathways that are involved in 
the self renewal behavior of CSCs, including 
Wnt/β-catenin and Notch, and Hedgehog 
signaling, which mediate the resistances against 
radiotherapy and chemotherapy.29,30
Stem cells of the colon crypt are the origin 
of colon mature cells. CRC cells are also 
suggested to originate from crypt stem cells 
undergoing a series of epigenetic and genetic 
alterations. Aberrant methylation plays an 
important role in early carcinogenesis and 
lead to altered gene expression and regulation, 
resulting in accumulation of damages to 
cell function and ultimately, malignant 
transformation. Aberrances in hypermethylation 
and hypomethylation act as different mechanism 
through the regulation of various genes during 
CSC carcinogenesis, and both of them play 
crucial roles in stem cell differentiation toward 
cancer cells. A large majority of epigenetic and 
genetic abnormalities that work coordinately 
in colorectal carcinogenesis are related to cell 
growth and division, indicating that the intrinsic 
abnormalities of CRC lie in dysregulation of 
basic cellular process. Detection of abnormal 
methylation can be used in cancer screening 
and early detection, while reversal of aberrant 
methylation using drugs may have potential in 
cancer therapy.32
Epigenetic and genetic abnormalities are 
definite risk factors for CRC, as DNA methylation 
and gene mutations are both found in colon 
precancerous and cancerous tissues. Epigenetic 
mechanisms, including DNA methylation, 
are actively involved in the regulation of 
normal intestinal stem and progenitor epithelial 
cells through the repression or activation of 
differentiation or proliferation genes.32-33
The concept of cancer stem cell (CSC) was 
proposed as studies found epigenetic and genetic 
aberrances in progenitor or precursor cells that 
have the capacity to differentiate into certain 
cell types.33 Research showed that the malignant 
transformation of cancer starts at very early stage 
when the cells are still at the stem cell stage.
Two models are currently available for 
explaining the process of CRC carcinogenesis: 
a) In the CRC somatic cell model, cancer 
cells are suggested to originate from normal 
mature epithelial cells. These cells undergo a 
series of epigenetic alterations, such as MLH1 
gene methylation, and genetic alterations, 
such as MSI pathway initiated by MMR gene 
mutation. Aberrant methylation and mutations 
are associated with CIN and further mutations 
in key regulatory genes, such as KRAS, 
BRAF, and lead to progression from low-grade 
abnormal proliferation (e.g. small adenoma) 
to high-grade abnormal proliferation (e.g. 
large adenoma or advanced adenoma). The 
accumulation of aberrant methylation and further 
mutations (TP53,TGFBR2 and BAX, etc) leads 
to malignant transformation of epithelial cells. 
Abnormal methylation and key gene mutations 
are regarded as the initial changes for epithelial 
cell transformation to ward cancer cells.6
b) The CSC model suggest that tumors are 
hierarchially organized and only CSCs posses 
cancer promoting properties. In the CRC 
cancer stem cell model, malignant changes are 
suggested to start at the stem or precursor cell 
level. Precursor cells are a type of partially 
differentiated stem cell which has the capacity 
to differentiate into one cell type, and therefore 
are also called unipotent stem cells. Epigenetic 
changes, such as aberrant methylation, may result 
in silencing of genes p16, SFRPs, GATA-4/-5 and 
APC in stem/precursor cells of adult cell renewal 
systems and may lock these cells into stem-like 
states that foster abnormal cell clonal expansion, 
and the stem/precursor cells are transformed into 
preinvasive cancer stem cells.34 The silencing 
of key genes can foster increased CRC-related 
pathway signaling (such as Wnt pathway), 
resulting in genomic instability and mutations 
in the downstream pathway genes, such as APC 
or β-catenin, and further activate these signaling 
pathways to foster colon tumorigenesis.35,36 
At this stage, preinvasive cancer stem cells 
turn into cancer stem cells that will ultimately 
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become cancer cells due to accumulation of 
epigenetic and genetic abnormalities. It is 
clear from the models that both epigenetic and 
genetic alterations play crucial roles in CRC 
carcinogenesis, while epigenetic alterations may 
be a predominant factor during early malignant 
transformation of colonic stem cell in the stem 
cell model.
The proposal of the CRC stem cell model has 
great significance in guiding CRC therapy. The 
current chemotherapies generally aim at mature 
cancer cells, not the CRC CSCs. Although these 
treatments can reduce the size of cancer tissue, 
they cannot completely kill CSCs that have higher 
proliferative potential and stronger resistance to 
chemotherapy than mature cancer cells. They can 
escape the chemotheapy and differentiate into 
mature cancer cells when therapy is withdrawn, 
resulting in cancer recurrence and metastasis. 
Therefore, development of therapy targeting 
CSCs has a therapeutic potential to achieve 
better treatment to suppress cancer growth and 
metastasis.32
Markers of Colorectal Cancer Stem Cells
Several stem cell markers, including CD133, 
CD44, CD24, CD166, LGR-5 and aldehyde 
dehydrogenase-1 (ALDH-1) are currently being 
developed as CR-CSCs markers (Tabel 1). Drug 
resistance exists in CR-CSCs may be associated 
with the slow growth of CR-CSCs in G0 stage. 
A large sample of clinical research conducted in 
501 CRC patients demonstrated that, tumors with 
CD133 overexpression showed more resistance 
in 5-FU based chemotherapy and the expression 
CD133 related to poor prognosis.37 MicroRNAs 
(miRNAs) also play a role in the regulation of cell 
proliferation and can regulate  CR-CSCs specific 
signal pathway to increase CR-CSCs drug 
resistance. For example, miRNA-140 inhibits the 
Table 1. The markers of colorectal cancer stem cells.17
Marker Function Significance
CD133 (prominin‑1) Pentaspan transmembrane glycoprotein, 
organization of plasma membrane
Tumor initiation in xenografts, colony formation, 
correlation with: Poor prognosis, ↓survival, 
recurrence, metastasis, resistance to therapy
CD44 Cell adhesion molecule, hyaluronic acid 
receptor
Tumor initiation in xenografts, colony formation, 
association with tumor stage, lymph node 
infiltration, prognosis and survival
CD166 (ALCAM) Cell adhesion molecule Tumor initiation in xenografts, colony formation, 
further enrichment, correlation with prognosis and 
survival
CD24 Cell adhesion molecule ↑Clonogenic ability, multilineage potential, further 
enrichment, correlation with invasiveness, 
differentiation and survival
ALDH‑1 Detoxifying enzyme, resistance to 
alkylating agents
Tumor initiation in xenografts, further enrichment, 
transition from colitis to cancer, mitochondrial 
isoform is highly↑in CRC
CD29 (β1‑integrin) Cell adhesion molecule Colony formation, in CRC↑, association with tumor 
stage, ↑mRNA in CRC
Msi‑1 RNA‑binding protein, maintenance of the 
undifferentiated state of SCs
Expression in CD133+ cells and spheroid cultures, 
↑in CRC, association with tumor stage, ↑mRNA in 
CRC
Wnt pathway activity, 
b‑catenin
Maintenance and proliferation of the SC 
reservoir
↑Activity is associated with: Clonogenicity and 
tumorigenicity, detection of low stage CRC cases 
with: Risk of relapse
LGR‑5 Wnt target gene, crypt base restriction, 
unknown function
↑Tumorigenicity, poor prognostic factor, metastasis 
formation, in a APC knockout mouse model 
LGR‑5+ cells form adenomas within weeks
EpCAM (ESA) Cell adhesion molecule Expression in CD133+ or CD44+ cells
CD26 Cell surface glycoprotein Tumor initiation and metastasis formation in a 
mouse model
Oct‑4, Sox‑2, Nanog, 
Lin‑28, Klf‑4, c‑myc
Transcription factors Correlation with poor prognosis, relapse, distant 
recurrence, resistance to therapy
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proliferation of CD133+high/CD44+high human 
CRC cells through regulating histone deacetylase 
4, leading to resistance to 5-FU.38
The exact relationship between CR-CSCs 
and chemotherapy is still unclear, several studies 
demonstrated that in CRC, CD133+ CR-CSCs 
survived after adjuvant chemotherapy. As the 
treatment dose increased, the expression of 
CD133 also increased in vitro.39,40
COLORECTAL  CSCS  AND THERAPEUTIC 
IMPLICATIONS
Currently, most of the interventional clinical 
trials are carried out on metastatic patients 
with the aim of temporarily controling tumor 
progression. However, with the increasing 
knowledge of colorectal CSC (CR-CSC) 
biology, several therapeutic options are 
becoming available. The effectiveness of CSC-
targeted therapies may be maximal on CSCs 
disseminated outside the tumor context, which 
may be vulnerable to combined therapies due 
to the absence of a protective niche. In fact, 
a partial targeting of disseminated CSCs may 
be empirically carried out in the clinic during 
adjuvant treatment. Although there is no formal 
proof that CSCs can be effectively targeted in 
CRC patients, it is extremely likely that adjuvant 
chemotherapy can kill disseminated CSCs that 
escape surgery. This would explain why there is 
a statistically significant curative advantage in 
the administration of adjuvant therapy in stage II 
and III patients.41 New targeted therapy strategies 
for advanced colon cancer are provided in Table 
2. The purpose of this therapy is to control the 
relevant pathways of tumor growth, survival and 
metastasis.13,14
Colorectal Cancer Targeted Therapy
Current therapies do not target the CSC. 
This could be the reason behind recurrence of 
tumor growth or resistance to treatment post 
therapy.39,40 Many studies have investigated 
different ways to target tumorigenesis. One focus 
of recent research has been the usage of markers. 
Markers are molecules on the cell surfaces of 
these mutated cells. These markers are used in 
attempts to identify potential target of therapy. 
Another form of targeting cancer growth is 
via pathways. The regulation of the stem cells 
survival is through the signaling pathway such 
as Wnt pathway. Markers for the mentioned 
pathways may enable us to locate  stem cells 
and monitor progression. CRC can be treated 
in the early stages via surgery, however if not 
diagnosed and treated in time, the rate of survival 
diminishes rapidly. All CRC chemotherapy 
treatments target the proliferative nature of 
the cancer cells in an attempt to minimize the 
growth. It seems as if the stem cells are not being 
targeted or perhaps provide resistance to the 
therapies themselves. The CSC may be capable 
of regenerating cells resistant to the therapy. The 
future of treatment of CRCs lies in the new and 
upcoming research on CSCs. The potential in 
CSC targeting via markers is vast in account of 
Table 2. Novel targeting approaches against colorectal cancer stem cells17
Gene/pathway Targeting mechanism Targeting mechanism
VEGF Bevacizumab, humanized anti‑VEGF 
mAb
FDA approved
EGFR Cetuximab, an mAb against the EGFR 
extracellular binding domain
FDA approved
IGF‑IR IGF‑IR inhibitor, AVE‑1642 Experimental
IL‑4 Anti‑IL‑4 neutralizing antibody Experimental
Aurora‑A kinase Specific gene silencing Experimental
Tcf/(3‑catenin complex) Small molecule inhibition Experimental
Notch pathway γ‑secretase inhibitor Experimental
BMP4 pathway Recombinant BMP4 Experimental
Thymosin β4 Specific gene silencing Experimental
VEGF=Vascular endothelial growth factor, EGFR=Epidermal growth factor receptor, IGF‑IR=Insulin‑like growth factor‑I 
receptor, IL‑4=Interleukin‑4, BMP=Bone morphogenesis protein, FDA=Food and Drug Administration
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the benefits regarding treatment. If these CSCs 
can be found and pathways better understood, 
chemoradiotherapy (CRT) resistance cancers can 
be targeted, offering a better prognosis than the 
current situation.42
Traditional chemotherapy should be 
combined with new strategies targeting CSCs 
to prevent tumor relapse and to provide a highly-
efficient and low toxic treatment for cancer 
therapy.43
Targeting the Molecular Signaling Pathways
Signaling pathways are essential for normal 
stem cells related to self-renewal, proliferation 
and differentiation; however, the dysregulation 
or aberrant activation of these key pathways 
may result in the formation of cancer stem 
cells (CSCs) which induce tumorigenesis. 
These important signaling pathways consist of 
Hedgehog (Hh), Notch,Wnt/β-catenin signaling 
pathway, high mobility group AT-hook 2 
(HMGA2), Bcl-2, Bmi-1, and more. The most 
studied and characterized pathways are Hh, 
Notch, Wnt/β-catenin signaling pathway, which 
are responsible for the formation of CSCs. 
Therefore, targeting these aberrant signaling 
pathways are important offers a new strategy for 
cancer therapy.43
The Wnt/β-catenin signaling pathway has a 
role in maintaining the phenotype of intestinal 
crypt stem cell. APC function loss or β-catenin 
mutation induce Wnt signaling disorder are the 
leading causes of most CRC. LGR5, a marker 
of intestinal stem cell could regulate CRC cell 
proliferation and survival through targetting the 
Wnt/β-catenin signaling pathway. CD44v6 is 
found to be expressed in all CR-CSCs, inhibition 
of phosphatidylinositol 3-kinase selectivity killed 
CD44v6 CR-CSCs and decreased metastatic 
growth.17,44-48
T h e  N o t c h  s i g n a l i n g  p a t h w a y  i s 
overexpressed in CR-CSCs, and plays a role in 
CR-CSCs tumorigenecity and self-renewal by 
inhibiting cell-cycle kinase inhibitor p27 and 
transcription factor ATOH1. In APCmin CRC 
model, γ-secretase inhibition mediated Notch 
signaling dysfunction induced the APC min 
proliferating cells in intestinal adenoma turning 
into goblet cells, then leading to the growth 
stagnation of tumor cells. BMP4 plays a key role 
in the development of physiological intestinal 
crypts. Mutation of BMP4 is signaling pathway 
(SMAD4 and BMPRIA) or blocking the BMP4 
signaling pathway by expression of BMP4 
antistatic agent. Noggin induces the development 
of intestinal crypts, cancer susceptibility 
syndrome, and juvenile polyposis syndrome. 
The expression of BMPR2 and SMAD4 
were also found in an immunohistochemical 
analysis of 72 sporadic CRC patients, revealing 
that blocking BMP4 signaling pathway can 
potentially contribute o the formation of 
colorectal tumor. In this aspect BMP4 could 
induce the differentiation of CD133 + CR-
CSCs, improving the sensitivity of oxaliplatin 
and 5-FU in the treatment of xenografted 
tumor. It is reported that, actin-binding peptide 
thymosin β4 (T β4) is overexpressed in CD133 
+ CR-CSCs. Targeting T β4 can damage the 
growth and migration of CR-CSCs in vitro, also 
through regulating integrin-linked kinase/Akt 
transduction cascades invivo can reduce the tunor 
size of CD133 +  CR-CSCs based xenografts in 
mice.17,49-53
Targeting CSCs Markers
Markers used to isolate, identify and enrich 
CSCs are also ideal targets for cancer therapy. 
Targeting cytotoxic drugs to CSCs with the help 
of stem cell surface markers provides a useful 
method to treat cancer. Also, the use of inhibitors 
targeting drug-detoxifying enzymes, drug-
efflux pumps, or transcription factors of CSCs 
represents a novel approach to target the CSCs 
and reduce cancer recurrence and metastasis.43
CONCLUSION
Chemotherapy  can only shrink tumors 
by killing the active tumor cells but miss the 
quiescent CSCs that lead to resistance and 
relapse, and may even enrich CSCs for a more 
resistant state, and usually include systemic and 
local toxicity. New treatments targeting CSCs 
are necessary for improving patient survival rate 
and prolonging life span. Thus, more precisely 
targeted therapies which can selectively target 
CSCs but spare normal stem cells are greatly 
needed. Molecular markers have therapeutic 
implications for individualized treatment in 
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colorectal cancer patients. Several biomarkers 
associated with predictive and prognostic values 
are available. The markers of colorecal cancer 
and targeting approaches against colorectal 
cancer stem cells are being developed.
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